Treatment prospects for autosomal-dominant polycystic kidney disease

Kidney International

Volumn 59, Issue 6, 2001, Pages 2005-2022

  Qian, Qi ^a   Harris, Peter C ^a   Torres, Vicente E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antimutagens; Antioxidants; EGF receptor; Fish oil; Soy protein; Tyrosine kinase inhibitors

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ANTIMUTAGENIC AGENT; ANTIOXIDANT; COLCHICINE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; EPIDERMAL GROWTH FACTOR RECEPTOR; FISH OIL; GLUCOCORTICOID; HYDRALAZINE; MATRIX METALLOPROTEINASE INHIBITOR; METHYLPREDNISOLONE; OLTIPRAZ; PACLITAXEL; POLYCYSTIN; PROBUCOL; PROTEIN TYROSINE KINASE INHIBITOR; RETINOID; SELENIUM; SOYBEAN PROTEIN; TAXANE DERIVATIVE; UNINDEXED DRUG; VINBLASTINE; VITAMIN D;

ANIMAL CELL; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; AUTOSOMAL DOMINANT DISORDER; CLINICAL TRIAL; DIET SUPPLEMENTATION; ENZYME INHIBITION; GENE MUTATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN CONTENT; RAT; REVIEW;

EID: 0034999513     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.0590062005.x     Document Type: Review

References (136)

1. Watnick T, Germino G: Molecular basis of autosomal dominant polycystic kidney disease. Semin Nephrol 19:327-343, 1999
2. Somlo S, Markowitz G: The pathogenesis of autosomal dominant polycystic kidney disease: An update. Curr Opin Nephrol Hypertens 9:385-394, 2000
3. Murcia N, Sweeney W Jr, Avner E: New insights into the molecular pathophysiology of polycystic kidney disease. Kidney Int 55:1187-11.97, 1999
4. Torres V: New insights into polycystic kidney disease and its treatment. Curr Opin Nephrol Hypertens 7:159-169, 1998
5. Grantham J: Polycystic kidney disease: Neoplasia in disguise. Am J Kidney Dis 15:110-116, 1990
6. Kelloff G: Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 78:199-334, 2000
7. Torra R, Badenas C, San Millan J, et al: A loss-of-function model for cystogenesis in human autosomal dominant polycystic kidney disease type 2. Am J Hum Genet 65:345-352, 1999
8. Pei Y, Watnick T, He N, et al: Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 10:1524-1529, 1999
9. Koptides M, Hadjimichael C, Koupepidou P, et al: Germinal and somatic mutations in the PKD2 gene of renal cysts in autosomal dominant polycystic kidney disease. Hum Mol Genet 8:509-513, 1999
10. Rossetti S, Strmecki L, Gamble V, et al: Mutation analysis of the entire PKD1 gene: Genetic and diagnostic implications, (submitted for publication)
11. Wu G, Somlo S: Molecular genetics and mechanism of autosomal dominant polycystic kidney disease. Mol Genet Metab 69:1-15, 2000
12. Lu W, Fan X, Basora N, et al: Late onset of renal and hepatic cysts in mice heterozygous for a targeted PKD1 mutation. Nat Genet 21:160-161, 1999
13. Kim K, Drummond I, Ibraghimov-Beskrovnaya O, et al: Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 97:1731-1736, 2000
14. Van Raay T, Burn T, Connors T, et al: A 2.5 kb polypyrimidine tract in the PKD1 gene contains at least 23 H-DNA-forming sequences. Microb Comp Genomics 1:317-327, 1996
15. Watnick T, Gandolph M, Weber H, et al: Gene conversion is a likely cause of mutation in PKD1. Hum Mol Genet 7:1239-1243, 1998
16. Gnarra J, Ward J, Porter F, et al: Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 94:9102-9107, 1997
17. Kobayashi T, Minowa O, Kuno J, et al: Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 59:1206-1211, 1999
18. Martin G, Ogburn C, Colgin L, et al: Somatic mutations are frequent and increase with age in human kidney epithelial cells. Hum Mol Genet 5:215-221, 1996
19. Ong A, Harris P, Davies D, et al: Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2/PKD1 cystic tissue. Kidney Int 56:1324-1333, 1999
20. Woo D: Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 333:18-25, 1995
21. Lanoix J, D'Agati V, Szabolcs M, Trudel M: Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene 13:1153-1160, 1996
22. Lager D, Qian Q, Bengal R, et al. The pck rat, a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 59:126-136, 2001
23. Takahashi H, Calvet J, Dittemore-Hoover D, et al: A hereditary model of slowly progressive polycystic kidney disease in the mouse. J Am Soc Nephrol 1:980-989, 1991
24. Lowden D, Lindermann G, Merlino G, et al: Renal cysts in transgenic mice expressing transforming growth factor-alpha. J Lab Clin Med 124:386-394, 1994
25. Stocklin E, Botteri F, Groner B: An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. J Cell Biol 122:199-208, 1993
26. Trudel M, D'Agati V, Costantini F: c-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int 39:665-671, 1991
27. Pritchard L, Sloane-Stanely J, Sharpe J, et al. A human PKD1 transgene generates functional polycystin-1 in mice and is associated with a cystic phenotype. Hum Mol Genet 9:2617-2627, 2000
28. Koptides M, Mean R, Demetriou K, et al: Genetic evidence or a trans-heterozygous model for cystogenesis in autosomal dominant polycystic kidney disease. Hum Mol Genet 9:447-452, 2000
29. Watnick T, He N, Wang K, et al: Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of transheterozygous mutations. Nat Genet 25:143-144, 2000
30. Yoder B, Richards W, Sommardahl C, et al: Functional correction of renal defects in a mouse model for ARPKD through expression of the cloned wild-type Tg737 cDNA. Kidney Int 50:1240-1248, 1996
31. Wilson P, Geng L, Li X, Burrow C: The PKD1 gene product, "Polycystin-1," is a tyrosine-phosphorylated protein that colocalizes with alpha 2 beta 1-integrin in focal clusters in adherent renal epithelia. Lab Invest 79:1311-1323, 1999
32. Huan Y, Van Adelsberg J: Polycystin-1, the PKD1 gene product, is in a complex containing E-cadherin and the catenins. J Clin Invest 104:1459-1468, 1999
33. Cai Y, Maeda Y, Cedzich A, et al: Identification and characterization of polycystin-2, the PKD2 gene product. J Biol Chem 274:28557-28565, 1999
34. Boudreau N, Jones P: Extracellular matrix and integrin signalling: The shape of things to come. Biochem J 339:481-488, 1999
35. Troyanovsky S: Mechanism of cell-cell adhesion complex assembly. Curr Opin Cell Biol 11:561-566, 1999
36. Kikuchi A: Regulation of beta-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 268:243-248, 2000
37. Morin P: Beta-catenin signaling and cancer. Bioessays 21:1021-1030, 1999
38. Daikha-Dahmane F, Narcy F, Dommergues M, et al: Distribution of alpha-integrin subunits in fetal polycystic kidney diseases. Pediatr Nephrol 11:267-273, 1997
39. Lo S, Yu Q, Degenstein L, et al: Progressive kidney degeneration in mice lacking tensin. J Cell Biol 136:1349-1361, 1997
40. Rocco M, Neilson E, Hoyer J, Ziyadeh F: Attenuated expression of epithelial cell adhesion molecules in murine polycystic kidney disease. Am J Physiol 262:F679-F686, 1992
41. Kim E, Arnould T, Sellin L, et al: The polycystic kidney disease 1 gene product modulates Wnt signaling. J Biol Chem 274:4947-4953, 1999
42. Charron A, Nakamura S, Bacallaeo R, Wandinger-Ness A: Compromised cytoarchitecture and polarized trafficking in autosomal dominant polycystic kidney disease cells. J Cell Biol 149:111-1.24, 2000
43. Bergin E, Levine J, Koh J, Lieberthal W: Mouse proximal tubular cell-cell adhesion inhibits apoptosis by a cadherin-dependent mechanism. Am J Physiol 278:F75S-F768, 2000
44. Romagnolo B, Berrebi D, Saadi-Keddoucci S, et al: Intestinal dysplasia and adenoma in transgenic mice after overexpression of an activated beta-catenin. Cancer Res 59:3875-3879, 1999
45. Grantham J, Cowley B Jr, Torres V: Progression of autosomal dominant polycystic kidney disease (ADPKD) to renal failure, in The Kidney: Physiology and Pathophysiology (vol 2), edited by Seldin D, Giebisch G, Philadelphia, Lippincott Williams & Wilkins, 2000, pp 2513-2536
46. Wilson P, Hovater JCC, Fortenberry J, Schlwiebert E: ATP release mechanisms in primary cultures of epithelia derived from the cysts of polycystic kidneys. J Am Soc Nephrol 10:21.8-229, 1999
47. Tanner G, Gretz N, Connors B, et al: Role of obstruction in autosomal dominant polycystic kidney disease in rats. Kidney Int 50:873-886, 1996
48. Bhattacharyya K, Bengal R, Larsen M, et al: Renal expression of CYP1A1 and CYP1B1 in polycystic kidneys of HAN:SPRD rats. (submitted for publication)
49. Anderson D: Antioxidant defenses against reactive oxygen species causing genetic and other damage. Mutat Res 350:103-108, 1996
50. Torres V, Bengal R, Litwiller R, Wilson D: Aggravation of polycystic kidney disease in HAN:SPRD rats by buthionine sulfoximine. J Am Soc Nephrol 8:1283-1291, 1996
51. Nagao S, Yamaguchi T, Kasahara M, et al: Effect of probucol in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 35:221-226, 2000
52. Torres V, Bengal R, Nickander K, et al: Renal concentration of alpha-tocopherol: Dependence on gender and lack of effect on polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis 31:687-693, 1998
53. Tomobe K, Philbrick D, Aukema H, et al: Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease. J Am Soc Nephrol 5:1355-1360, 1994
54. Ogborn M, Sareen S: Amelioration of polycystic kidney disease by modification of dietary protein intake in the rat. J Am Soc Nephrol 6:1649-1654, 1995
55. Jarusiripipat C, Shapiro J, Chan L, Schrier R: Reduction of remnant nephron hypermetabolism by protein restriction. Am J Kidney Dis 18:367-374, 1991
56. Tomobe K, Philbrick D, Ogborn M, et al: Effect of dietary soy protein and genistein on disease progression in mice with polycystic kidney disease. Am J Kidney Dis 1:55-61, 1998
57. Ogborn M, Bankovic-Calic N, Shoesmith C, et al: Soy protein modification of rat polycystic kidney disease. Am J Palhol 274:F541-F549, 1998
58. Ogborn M, Nitschmann E, Weiler H, Bankovic-Calic N: Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney Int 57:159-166. 2000
59. Yoshida I, Bengal R, Torres V: Gender dependent effect of L-NAME on polycystic kidney disease in HAN. SPRD rats. Am J Kidney Dis 35:930-936, 2000
60. Rose D, Connolly J: Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83:217-244, 1999
61. Aukema H, Housini I, Rawling J: Dietary soy protein effects on disease and IGF-I in male and female Han:SPRD-cy rats. Kidney Int 59:52-61, 2001
62. Ogborn M, Nitschmann E, Weiler H, et al: Flaxseed ameliorates interstitial nephritis in rat polycystic kidney disease. Kidney Int 55:417-423, 1999
63. Aukema H, Yamaguchi T, Takahashi H, et al: Effects of dietary fish oil on survival and renal fatty acid composition in murine polycystic kidney disease. Nutr Res 12:1383-1392, 1992
64. Torres V, Mujwid D, Wilson D, Holley K: Renal cystic disease and ammoniagenesis in Han:SPRD rats. J Am Soc Nephrol 5:1193-1200, 1994
65. Tanner G: Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 9:1242-1248, 1998
66. Torres V, Cowley BJ, Branden M, et al: Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease. Exp Nephrol (in press)
67. Tanner G, Vuayalakshmi K, Tanner J: Effects of potassium citrate/citric acid intake in a mouse model of polycystic kidney disease. Nephron 84:270-273, 2000
68. Klapper L, Kirschbaum M, Sela M, Yarden Y: Biochemical and clinical implications of the erbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25-79, 2000
69. Moghal N, Neel B: Integration of growth factor, extracellular matrix, and retinoid signals during bronchial epithelial cell differentiation. Mol Cell Biol 18:6666-6678, 1998
70. Gattone VI: Defective epidermal growth factor gene expression in mice with polycystic kidney disease. Dev Biol 138:225-230, 1990
71. Cowley BJ, Rupp J: Abnormal expression of epidermal growth factor and sulfated glycoprotein SGP-2 messenger RNA in a rat model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 6:1679-1681, 1995
72. Wilson P, Du J, Norman J: Autocrine, endocrine,and paracrine regulation of growth abnormalities in autosomal dominant polycystic kidney disease. Eur J Cell Biol 61:131-138, 1993
73. Lee D, Chan K, Chan S: Expression of transforming growth factor alpha and epidermal growth factor receptor in adult polycystic kidney disease. J Urol 159:291-296, 1998
74. Du J, Wilson P: Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am J Physiol 269:C487-C495, 1995
75. Sweeney W Jr, Chen Y, Nakanishi K, et al: Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 57:33-40, 2000
76. Herrera G: C-erb B-2 amplification in cystic renal disease. Kidney Int 40:509-513, 1991
77. Gattone VN, Kuenstler K, Lindemann G, et al: Renal expression of a transforming growth factor-alpha transgene accelerates the progression of inherited, slowly progressive polycystic kidney disease in the mouse. J Lab Clin Med 127:214-222, 1996
78. Avner E, Sweeney W Jr: Polypeptide growth factors in metanephric growth and segmental nephron differentiation. Pediatr Nephrol 4:372-377, 1990
79. Neufeld T, Douglass D, Grant M, et al: In vitro formation and expansion of cysts derived from human renal cortex epithelial cells. Kidney Int 41:1222-1236, 1992
80. Pugh J, Sweeney WJ, Avner E: Tyrosine kinase activity of the EGF receptor in murine metanephric organ culture. Kidney Int 47:774-781, 1995
81. Sweeney W, Futey L. Frost P, Avner E: In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor. Kidney Int 56:406-413, 1999
82. Richards W, Sweeney W, Yoder B, et al: Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest 101:935-939, 1998
83. Fry D: Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des 15:3-16, 2000
84. Noonberg S, Benz C: Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs 59:753-767, 2000
85. Campbell SL, Khosravi-Far R, Rossman KL, et al: Increasing complexity of Ras signaling. Oncogene 17:1395-1413, 1998
86. 86. Schaffner D, Barrios R, Massey C, et al: Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am J Pathol 142:1051-1060, 1993
87. Oliff A: Farnesyltransferase inhibitors: Targeting the molecular basis of cancer. Biochim Biophys Acta 1423:C19-C30, 1999
88. Hill B, Perrin D, Kruczynski A: Inhibition of RAS-targeted prenylation: Protein farnesyl transferase inhibitors revisited. Crit Rev Oncol Hematol 33:7-23, 2000
89. Gile R, Cowley B Jr, Gattone VII, et al: Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 26:501-507, 1995
90. Grantham J: Fluid secretion, cellular proliferation, and the pathogenesis of renal epithelial cysts. J Am Soc Nephrol 3:1843-1857, 1993
91. Devuyst O, Beauwens R: Ion transport and cystogenesis: The paradigm of autosomal dominant polycystic kidney disease. Adv Nephrol 28:439-479, 1998
92. Yamaguchi T, Felling J, Ramaswamy N, et al: cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57:1460-1471, 2000
93. Hanaoka K, Guggino W: cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 11:1179-1187, 2000
94. Ciardiello F, Tortora G: Interactions between the epidermal growth factor receptor and type I protein kinase A: Biological significance and therapeutic implications. Clin Cancer Res 4:821-828,1998
95. Ciardiello F, Caputo R, Biano R, et al: Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J Natl Cancer Inst 90:17-1094, 1998
96. Cho-Chung Y, Nesterova M, Pepe S, et al: Antisense DNA-targeting protein kinase A-RIA subunit: A novel approach to cancer treatment. Front Biosci. 4:D898-D907, 1999
97. Gibbs J: Anticancer drug targets: Growth factors and growth factor signaling. J Clin Invest 105:9-13, 2000
98. Aukema H, Chapkin R, Tomobe K, et al: In vivo formation of polyphosphoinositide isomers and association with progression of murine polycystic kidney disease. Exp Mol Pathol 57:39-46, 1992
99. Jarvis W, Grant S: Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs 17:227-240, 1999
100. Vojtek A, Der Channing J: Increasing complexity of the Ras signaling pathway. J Biol Chem 273:19925-19928, 1998
101. Wilson P: Pathogenesis of polycystic kidney disease: Altered cellular function, in Potycystic Kidney Disease, edited by Watson M, Torres V, Oxford, Oxford University Press, 1996, pp 125-163
102. Du W, Liu A, Prendergast G: Activation of the P13'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 59:4208-4212, 1999
103. Deshmukh G, Radin N, Gattone V, Shayman J: Abnormalities of glycosphingolipid sulfatide, and ceramide in the polycystic (cpk/ cpk) mouse. J Lipid Res 35:1611-1618, 1994
104. Chatterjee S, Sm W, Wilson P, Mazumdar A: Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. J Lipid Res 37:1334-1344: 1996
105. Shukla G, Shukla A, Inokuchi J, Radin N: Rapid kidney changes resulting from glycosphingolipid depletion by treatment with a glucosyltransferase inhibitor. Biochim Biophys Acta 1083:101-108, 1991
106. Kurie J: The biologic basis for the use of retinoids in cancer prevention and treatment. Curr Opin Oncol 11:497-502, 1999
107. Sabichi A, Lerner S, Grossman H, Lippman S: Retinoids in the chemoprevention of bladder cancer. Curr Opin Oncol 10:479-484, 1998
108. Altierei P, Caridi G, Chiesa V, et al: N-(4-hydroxyphenyl) retinamide inhibits cystogenesis by polycystic epithelial cell line in vitro. Life Sci 64:PL259-PL265, 1999
109. Verstuyf A, Segaert S, Verlinden L, et al: Recent developments in the use of vitamin D analogues. Curr Opin Nephrol Hypertens 7:397-403: 1998
110. Ali S, Wong V, Kikly K, et al: Apoptosis in polycystic kidney disease: Involvement of caspases. Am J Physiol 278:R763-R769, 2000
111. Ostom L, Tang M, Grus P, Dressler G: Reduced Pax2 gene dosage increases apoptosis and slows the progression of renal cystic disease. Dev Biol 219:250-258, 2000
112. Sellers W, Fisher D: Apoptosis and cancer drug targeting. J Clin Invest 104:1655-1661, 1999
113. Haunsteter A, Izumo S: Toward antiapoptosis as a new treatment modality. Circ Res 86:371-376, 2000
114. Woo D, Tabancay A Jr, Wang C: Microtubule active taxanes inhibit polycystic kidney disease progression in cpk mice. Kidney Int 51:1613-1618, 1997
115. Yeung T, Germond C, Chen X, Wang Z: The mode of action of taxol: Apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res Commun 263:398-404, 1999
116. Fan W: Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 57:1215-1221, 1999
117. Martinez J, Cowley B, Gattone VII, et al: The effect of paclitaxel on the progression of polycystic kidney disease in rodents. Am J Kidney Dis 29:435-444, 1997
118. Sommardahl C, Woychik R, Sweeney W, et al: Efficacy of taxol in the orpk mouse model of polycystic kidney disease. Pediatr Nephrol 11:728-733, 1997
119. O'Sullivan D, Torres V, Gabow P, et al: Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 32:976-983, 1998
120. Everson G, Emmett M, Brown W, et al: Functional similarities of hepatic cystic and biliary epithelium: Studies of fluid constituents and in vivo secretion in response to secretin. Hepatology 11:557-565, 1990
121. Sandhu S, Silbiger S, Lei J, Neugarten J: Effects of sex hormones on fluid and solute transport Madin-Darby canine kidney cells. Kidney Int 51:1535-1539, 1997
122. Gattone VI, Maser R, Tian C, et al. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 24:309-318, 1999
123. Chauveau D, Pirson Y, Le Moine A, et al: Extrarenal manifestations in autosomal dominant polycystic kidney disease. Adv Nephrol Necker Hosp 26:265-289, 1997
124. Barlaam B, Bird T, Lambert-Van Der Brempt C, et al: New α-substituted succinate-based hydroxamic acids as TNFα convertase inhibitors. J Med Chem 42:4890-4908, 1999
125. Newton R, Decicco C: Therapeutic potential and strategies for inhibiting tumor necrosis factor-α. J Med Chem 13:2295-2314, 1999
126. Gattone VII, Cowley B Jr, Barash B, et al: Methylprednisolone retards the progression of inherited polycystic kidney disease in rodents. Am J Kidney Dis 25:302-313, 1995
127. Yip D, Ahmad A, Karapetis C, et al: Matrix metalloproteinase inhibitors: Applications in oncology. Invest New Drugs 17:387-399, 1999
128. Nakamura T, Ushiyama C, Suzuki S, et al: Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease. Am J Nephrol 20:32-36, 2000
129. Keith D, Torres V, Johnson C, Holley K: Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis 24:491-498, 1994
130. Ogborn M, Sareen S, Pinette G: Cilazapril delays progression of hypertension and uremia in rat polycystic kidney disease. Am J Kidney Dis 26:942-946, 1995
131. Kennefick T, Al-Nimri M, Oyama T, et al: Hypertension and renal injury in experimental polycystic kidney disease. Kidney Int 56:2181-2190, 1999
132. Munemura C, Uemasu J, Kawasaki H: Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: Possible evidence of heterogeneity in cystogenesis. Am J Kidney Dis 24:561-568, 1994
133. Giusti R, Neri M, Angelini D, et al: Plasma concentration of endothelin and arterial pressure in patients with ADPKD. Contrib Nephrol 115:118-121, 1995
134. Nakamura T, Ebihara I, Fukui M, et al: Increased endothelin and endothelin receptor mRNA expression in polycystic kidneys of cpk mice. J Am Soc Nephrol 4:1064-1072, 1993
135. Hocher B, Thone-Reineke C, Rohmeiss P, et al: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99:1380-1389, 1997
136. Hocher B, Zart R, Schwarz A, et al: Renal endothelin system in polycystic kidney disease. J Am Soc Nephrol 9:1169-1177, 1998